G Protein-Coupled Receptor Kinases in Cardiovascular Disease: Why "Where" Matters

Trends in Cardiovascular Medicine

Volumn 22, Issue 8, 2012, Pages 213-219

  Kamal, Fadia A ^a   Travers, Joshua G ^a   Blaxall, Burns C ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE;

ADIPOCYTE; ADRENAL GLAND; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; HEART FUNCTION; KIDNEY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

CARDIOVASCULAR DISEASES; G-PROTEIN-COUPLED RECEPTOR KINASES; HUMANS; INSULIN RESISTANCE; KIDNEY DISEASES; MOLECULAR STRUCTURE; PHOSPHORYLATION; RECEPTORS, ADRENERGIC; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84869037113     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.07.023     Document Type: Review

References (70)

1. Banday A.A., Fazili F.R., Lokhandwala M.F. Insulin causes renal dopamine D1 receptor desensitization via GRK2-mediated receptor phosphorylation involving phosphatidylinositol 3-kinase and protein kinase C. Am J Physiol Renal Physiol 2007, 293:F877-F884.
2. Belmonte S.L., Blaxall B.C. G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ Res 2011, 109:309-319.
3. Bonita R.E., Raake P.W., Otis N.J., et al. Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: A biomarker for left ventricular function. Clin Transl Sci 2010, 3:14-18.
4. Brinks H., Boucher M., Gao E., et al. Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ Res 2010, 107:1140-1149.
5. Casey L.M., Pistner A.R., Belmonte S.L., et al. Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. Circ Res 2010, 107:532-539.
6. Chen E.P., Bittner H.B., Akhter S.A., et al. Myocardial function in hearts with transgenic overexpression of the G protein-coupled receptor kinase 5. Ann Thorac Surg 2001, 71:1320-1324.
7. Ciccarelli M., Chuprun J.K., Rengo G., et al. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation 2011, 123:1953-1962.
8. Clark A.L., Cleland J.G. The control of adrenergic function in heart failure: therapeutic intervention. Heart Fail Rev 2000, 5:101-114.
9. Cohn H.I., Harris D.M., Pesant S., et al. Inhibition of vascular smooth muscle G protein-coupled receptor kinase 2 enhances α1D-adrenergic receptor constriction. Am J Physiol Heart Circ Physiol 2008, 295:H1695-H1704.
10. Cohn H.I., Xi Y., Pesant S., et al. G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in black Americans. Hypertension 2009, 54:71-76.
11. Dorn G.W. GRK mythology: G-protein receptor kinases in cardiovascular disease. J Mol Med Berl 2009, 87:455-463.
12. Eckhart A.D., Koch W.J. Expression of a beta-adrenergic receptor kinase inhibitor reverses dysfunction in failing cardiomyocytes. Mol Ther 2002, 5:74-79.
13. Eckhart A.D., Ozaki T., Tevaearai H., et al. Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure. Mol Pharmacol 2002, 61:749-758.
14. Felder R.A., Jose P.A. Mechanisms of disease: The role of GRK4 in the etiology of essential hypertension and salt sensitivity. Nat Clin Pract Nephrol 2006, 2:637-650.
15. Felder R.A., Sanada H., Xu J., et al. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci U S A 2002, 99:3872-3877.
16. Feldman R.D. Defective venous beta-adrenergic response in borderline hypertensive subjects is corrected by a low sodium diet. J Clin Invest 1990, 85:647-652.
17. Feldman R.D., Gros R. Impaired vasodilator function in hypertension: The role of alterations in receptor-G protein coupling. Trends Cardiovasc Med 1998, 8:297-305.
18. Freedman N.J., Kim L.K., Murray J.P., et al. Phosphorylation of the platelet-derived growth factor receptor-β and epidermal growth factor receptor by G protein-coupled receptor kinase-2: Mechanisms for selectivity of desensitization. J Biol Chem 2002, 277:48261-48269.
19. Freeman K., Lerman I., Kranias E.G., et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 2001, 107:967-974.
20. Garcia-Guerra L., Nieto-Vazquez I., Vila-Bedmar R., et al. G protein-coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity. Diabetes 2010, 59:2407-2417.
21. Gros R., Benovic J.L., Tan C.M., Feldman R.D. G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest 1997, 99:2087-2093.
22. Gros R., Chorazyczewski J., Meek M.D., et al. G-protein-coupled receptor kinase activity in hypertension: Increased vascular and lymphocyte G-protein receptor kinase-2 protein expression. Hypertension 2000, 35:38-42.
23. Haga K., Ogawa H., Haga T., Murofushi H. GTP-binding-protein-coupled receptor kinase 2 (GRK2) binds and phosphorylates tubulin. Eur J Biochem 1998, 255:363-368.
24. Harding V.B., Jones L.R., Lefkowitz R.J., et al. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci U S A 2001, 98:5809-5814.
25. Hata J.A., Williams M.L., Schroder J.N., et al. Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: Lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. J Card Fail 2006, 12:360-368.
26. Huang C.C., Tesmer J.J. Recognition in the face of diversity: Interactions of heterotrimeric G proteins and G protein-coupled receptor (GPCR) kinases with activated GPCRs. J Biol Chem 2011, 286:7715-7721.
27. Huang Z.M., Gold J.I., Koch W.J. G protein-coupled receptor kinases in normal and failing myocardium. Front Biosci J Virtual Libr 2012, 17:3047-3060.
28. Izzo R., Cipolletta E., Ciccarelli M., et al. Enhanced GRK2 expression and desensitization of βAR vasodilatation in hypertensive patients. Clin Transl Sci 2008, 215-220.
29. Jaber M., Koch W.J., Rockman H., et al. Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function. Proc Natl Acad Sci U S A 1996, 93:12974-12979.
30. Keys J.R., Zhou R.H., Harris D.M., Druckman C.A., Eckhart A.D. Vascular smooth muscle overexpression of G protein-coupled receptor kinase 5 elevates blood pressure, which segregates with sex and is dependent on Gi-mediated signaling. Circulation 2005, 112:1145-1153.
31. Kim J., Ahn S., Ren X.R., et al. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci U S A 2005, 102:1442-1447.
32. Liggett S.B., Cresci S., Kelly R.J., et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008, 14:510-517.
33. Liu S., Premont R.T., Kontos C.D., et al. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 2005, 11:952-958.
34. Lodowski D.T., Tesmer V.M., Benovic J.L., Tesmer J.J. The structure of G protein-coupled receptor kinase (GRK)-6 defines a second lineage of GRKs. J Biol Chem 2006, 281:16785-16793.
35. Lymperopoulos A., Rengo G., Funakoshi H., et al. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med 2007, 13:315-323.
36. Lymperopoulos A., Rengo G., Zincarelli C., et al. Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J Am Coll Cardiol 2011, 57:356-365.
37. Martini J.S., Raake P., Vinge L.E., et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A 2008, 105:12457-12462.
38. Morisco C., Lembo G., Trimarco B. Insulin resistance and cardiovascular risk: New insights from molecular and cellular biology. Trends Cardiovasc Med 2006, 16:183-188.
39. Morris G.E., Nelson C.P., Standen N.B., et al. Endothelin signalling in arterial smooth muscle is tightly regulated by G protein-coupled receptor kinase 2. Cardiovasc Res 2010, 85:424-433.
40. Nishi A., Eklöf A.C., Bertorello A.M., Aperia A. Dopamine regulation of renal Na+,K(+)-ATPase activity is lacking in Dahl salt-sensitive rats. Hypertension 1993, 21:767-771.
41. O'Connell D.P., Ragsdale N.V., Boyd D.G., et al. Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension 1997, 29:115-122.
42. Oyama N., Urasawa K., Kaneta S., et al. Angiotensin converting enzyme inhibitors attenuated the expression of G-protein coupled receptor kinases in heart failure patients. Circ 2006, J70:362-363.
43. Patel C.B., Noor N., Rockman H.A. Functional selectivity in adrenergic and angiotensin signaling systems. Mol Pharmacol 2010, 78:983-992.
44. Patwardhan P., Miller W.T. Processive phosphorylation: Mechanism and biological importance. Cell Signal 2007, 19:2218-2226.
45. Perrino C., Naga Prasad S.V., Mao L., et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest 2006, 116:1547-1560.
46. Ping P., Anzai T., Gao M., Hammond H.K. Adenylyl cyclase and G protein receptor kinase expression during development of heart failure. Am J Physiol 1997, 273:H707-H717.
47. Pitcher J.A., Fredericks Z.L., Stone W.C., et al. Phosphatidylinositol 4,5-bisphosphate (PIP2)-enhanced G protein-coupled receptor kinase (GRK) activity: Location, structure, and regulation of the PIP2 binding site distinguishes the GRK subfamilies. J Biol Chem 1996, 271:24907-24913.
48. Pitcher J.A., Inglese J., Higgins J.B., et al. Role of beta gamma subunits of G proteins in targeting the beta-adrenergic receptor kinase to membrane-bound receptors. Science 1992, 257:1264-1267.
49. Raake P.W., Vinge L.E., Gao E., et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res 2008, 103:413-422.
50. Rengo G., Leosco D., Zincarelli C., et al. Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. Am J Physiol Heart Circ Physiol 2010, 298:H2032-H2038.
51. Rengo G., Lymperopoulos A., Zincarelli C., et al. Myocardial adeno-associated virus serotype 6-βARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009, 119:89-98.
52. Rengo G., Lymperopoulos A., Zincarelli C., et al. Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart failure. Br J Pharmacol 2012, 166:2430-2440.
53. Rockman H.A., Chien K.R., Choi D.J., et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A 1998, 95:7000-7005.
54. Rockman H.A., Choi D.J., Akhter S.A., et al. Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem 1998, 273:18180-18184.
55. Rockman H.A., Choi D.J., Rahman N.U., et al. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci U S A 1996, 93:9954-9959.
56. Sanada H., Yatabe J., Midorikawa S., et al. Amelioration of genetic hypertension by suppression of renal G protein-coupled receptor kinase type 4 expression. Hypertension 2006, 47:1131-1139.
57. Shah A.S., White D.C., Emani S., et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001, 103:1311-1316.
58. Siderovski D.P., Hessel A., Chung S., et al. A new family of regulators of G-protein-coupled receptors?. Curr Biol CB 1996, 6:211-212.
59. Sorriento D., Santulli G., Fusco A., et al. Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-kappaB-dependent hypertrophic gene expression. Hypertension 2010, 56:696-704.
60. Stoffel R.H., Randall R.R., Premont R.T., et al. Palmitoylation of G protein-coupled receptor kinase, GRK6. Lipid modification diversity in the GRK family. J Biol Chem 1994, 269:27791-27794.
61. Takagi C., Urasawa K., Yoshida I., et al. Enhanced GRK5 expression in the hearts of cardiomyopathic hamsters, J2N-k. Biochem Biophys Res Commun 1999, 262:206-210.
62. Trivedi M., Lokhandwala M.F. Rosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats. Am J Physiol Renal Physiol 2005, 289:F298-F304.
63. Umrani D.N., Banday A.A., Hussain T., Lokhandwala M.F. Rosiglitazone treatment restores renal dopamine receptor function in obese Zucker rats. Hypertension 2002, 40:880-885.
64. Usui I., Imamura T., Babendure J.L., et al. G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both Galphaq/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes. Mol Endocrinol 2005, 19:2760-2768.
65. Usui I., Imamura T., Satoh H., et al. GRK2 is an endogenous protein inhibitor of the insulin signaling pathway for glucose transport stimulation. EMBO J 2004, 23:2821-2829.
66. Vinge L.E., von Lueder T.G., Aasum E., et al. Cardiac-restricted expression of the carboxyl-terminal fragment of GRK3 uncovers distinct functions of GRK3 in regulation of cardiac contractility and growth: GRK3 controls cardiac alpha1-adrenergic receptor responsiveness. J Biol Chem 2008, 283:10601-10610.
67. Völkers M., Weidenhammer C., Herzog N., et al. The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition. Circ Res 2011, 108:27-39.
68. Watanabe H., Xu J., Bengra C., et al. Desensitization of human renal D1 dopamine receptors by G protein-coupled receptor kinase 4. Kidney Int 2002, 62:790-798.
69. White D.C., Hata J.A., Shah A.S., et al. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci U S A 2000, 97:5428-5433.
70. Zhou R.H., Pesant S., Cohn H.I., et al. Negative regulation of VEGF signaling in human coronary artery endothelial cells by G protein-coupled receptor kinase 5. Clin Transl Sci 2009, 2:57-61.